Radical Numerics administers AI-designed bacteriophages to human patient
San Francisco-based AI lab Radical Numerics announced it administered a cocktail of AI-designed bacteriophages to a human patient under a compassionate-use protocol. This marks the first clinical application of phages generated by their newly unveiled Omnii-1 model. The therapy targets antimicrobial-resistant bacteria, offering a precise alternative to broad-spectrum antibiotics. While the lab claims success, final efficacy results remain pending, highlighting AI's growing role in bioscience.
Key points
- Radical Numerics, a San Francisco-based AI laboratory specializing in bioscience, announced the administration of AI-designed bacteriophages to a human patient.
- The treatment utilized a cocktail of phages generated by Omnii-1, a new AI model unveiled by the company this week.
- This event is described as the first instance of AI-designed phages being administered to a human under a compassionate-use arrangement.
- The therapy aims to combat antimicrobial-resistant bacteria by targeting specific strains, potentially preserving beneficial gut flora unlike broad-spectrum antibiotics.
- Previous AI phage research, including work by Stanford University and the Arc Institute, focused on targeting E. coli, but Radical Numerics claims this is the first human application.
- Final results of the treatment are not yet fully disclosed, with the lab indicating that comprehensive efficacy data is still being evaluated.
Radical Numerics, a San Francisco-based artificial intelligence laboratory focused on bioscience, has announced the administration of a therapeutic cocktail containing AI-designed bacteriophages to a human patient. The company claims this marks the first time phages generated by its proprietary AI model have been used in a human under a compassionate-use protocol. The treatment leverages Omnii-1, a new AI model publicly unveiled by the lab this week, which was used to design viable viruses that specifically infect bacteria.
The development addresses the growing challenge of antimicrobial resistance, where traditional antibiotics are increasingly ineffective. Bacteriophages offer a potential advantage over conventional antibiotics by targeting specific bacterial strains, thereby sparing beneficial gut bacteria that are often disrupted by broad-spectrum treatments. While the therapeutic use of phages is not new, the integration of AI to accelerate their engineering represents a significant shift in bioscience. Previous efforts, such as those by researchers at Stanford University and the Arc Institute, successfully created AI-designed phages targeting E. coli, but Radical Numerics asserts that this recent administration is the first to involve a human patient.
Despite the milestone, the lab has cautioned that final results are not yet fully confirmed. The company is still evaluating the comprehensive efficacy of the treatment, indicating that while the initial administration was successful, broader conclusions about the therapy's long-term viability are pending. This move underscores the expanding role of artificial intelligence in drug discovery and personalized medicine, potentially offering new tools in the fight against resistant pathogens.
Sources
The WireByte editorial team synthesises technology news from multiple primary sources, verifies the facts, and links every source. Articles are produced with AI assistance and reviewed under our editorial policy.
